|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OGN |
Gene summary for OGN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OGN | Gene ID | 4969 |
| Gene name | osteoglycin | |
| Gene Alias | OG | |
| Cytomap | 9q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A8K0R3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4969 | OGN | ATC13 | Human | Thyroid | ATC | 3.82e-98 | 3.08e+00 | 0.34 |
| 4969 | OGN | ATC5 | Human | Thyroid | ATC | 8.94e-102 | 3.13e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | CRC |  |
| Stomach | GC |  |
| Stomach | CAG with IM |  |
| Stomach | CSG |  |
| Stomach | CAG |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003300214 | Thyroid | ATC | muscle cell proliferation | 107/6293 | 248/18723 | 1.03e-03 | 5.47e-03 | 107 |
| GO:004865916 | Thyroid | ATC | smooth muscle cell proliferation | 81/6293 | 184/18723 | 2.02e-03 | 9.60e-03 | 81 |
| GO:004866016 | Thyroid | ATC | regulation of smooth muscle cell proliferation | 78/6293 | 180/18723 | 4.00e-03 | 1.73e-02 | 78 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OGN | SNV | Missense_Mutation | c.839N>C | p.Gly280Ala | p.G280A | P20774 | protein_coding | tolerated(0.82) | benign(0.026) | TCGA-A2-A04X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| OGN | SNV | Missense_Mutation | c.226N>C | p.Asp76His | p.D76H | P20774 | protein_coding | deleterious(0.01) | probably_damaging(0.972) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| OGN | SNV | Missense_Mutation | c.356A>C | p.Lys119Thr | p.K119T | P20774 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OGN | SNV | Missense_Mutation | c.334N>C | p.Asp112His | p.D112H | P20774 | protein_coding | deleterious(0.01) | benign(0.367) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| OGN | SNV | Missense_Mutation | c.334N>A | p.Asp112Asn | p.D112N | P20774 | protein_coding | tolerated(0.06) | benign(0.055) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| OGN | SNV | Missense_Mutation | novel | c.565C>A | p.Leu189Ile | p.L189I | P20774 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OGN | SNV | Missense_Mutation | novel | c.597N>G | p.Ile199Met | p.I199M | P20774 | protein_coding | deleterious(0.01) | possibly_damaging(0.591) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| OGN | SNV | Missense_Mutation | c.43N>T | p.Pro15Ser | p.P15S | P20774 | protein_coding | tolerated(0.14) | possibly_damaging(0.709) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| OGN | SNV | Missense_Mutation | rs764235963 | c.445G>A | p.Asp149Asn | p.D149N | P20774 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| OGN | SNV | Missense_Mutation | c.479N>T | p.Asp160Val | p.D160V | P20774 | protein_coding | deleterious(0.02) | possibly_damaging(0.863) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |